Drug Profile
Research programme: HSP90 heat-shock protein inhibitors - Synta Pharmaceuticals
Alternative Names: STA-12-1474; STA-1474Latest Information Update: 05 Aug 2016
Price :
$50
*
At a glance
- Originator Synta Pharmaceuticals
- Class Triazoles
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 22 Jul 2016 Synta Pharmaceuticals has been acquired and merged into Madrigal Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)